Antoni Wiedlocha funded by the EEA Poland-Norway grants
Antoni Wiedlocha
The proposal "Novel targeted therapy based on dual warhead conjugates against FGFR dependent cancers", with senior scientist Antoni Wiedlocha at Department of Molecular Cell Biology, Institute for Cancer Research, as Norwegian partner and professor Jacek Otlewski at the University of Wroclaw as Polish parther, has been awarded funding from the EEA Poland-Norway grants under the "Applied Research" programme.
Links:
From the National Centre for Research and Development in Poland:
Published in Level 2 journals, first or last author from Oslo University Hospital.
Ramadan DJ, Kichula KM, Tao S, Porfilio T, Lande A, Fluge Ø, Mella O, Strand EB, Saugstad OD, Norman PJ, Lie BA, Viken MK(2025) Killer cell immunoglobulin-like receptor (KIR) alleles suggested to be associated with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) Brain Behav Immun, 106098(in press) DOI 10.1016/j.bbi.2025.106098, PubMed 40897283
Beichmann B, Sollerud EP, Warmbrodt NS, Ottestad I, Paulsen MM, Henriksen C, Paur I(2025) Measured and predicted energy expenditure among patients with distal bowel cancer: Results from the GAIN-project Clin Nutr, 53, 88-98(in press) DOI 10.1016/j.clnu.2025.08.022, PubMed 40897149
Vandraas KF, Hjorth S, Trewin-Nybråten CB, Ursin G, Botteri E, Andreassen BK, Reinertsen KV, Blix ES, Naume B, Støer NC(2025) Anti-Her2 therapy patterns in metastatic breast cancer-Real-world data suggest undertreatment Int J Cancer(in press) DOI 10.1002/ijc.70120, PubMed 40892038